Santhera Pharmaceuticals Holding .../ CH1276028821 /
| 2024-07-24 4:45:21 PM | Chg. - | Volume | Bid10:22:01 AM | Ask10:35:49 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 9.31CHF | - | 487 Turnover: 4,540.45 |
9.16Bid Size: 61 | 9.40Ask Size: 182 | 115.6 mill.CHF | - | 2.11 |
GlobeNewswire
06-18
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
GlobeNewswire
06-18
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow ...
GlobeNewswire
06-10
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix
GlobeNewswire
04-25
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of ...
GlobeNewswire
03-27
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority R...
GlobeNewswire
03-14
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
GlobeNewswire
02-14
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) ...
GlobeNewswire
02-13
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier t...
GlobeNewswire
01-15
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Mus...
GlobeNewswire
01-12
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy ...
GlobeNewswire
2023-12-18
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscul...
GlobeNewswire
2023-12-07
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
GlobeNewswire
2023-10-27
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular ...
GlobeNewswire
2023-10-13
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treat...
GlobeNewswire
2023-09-07
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2022-03-29
Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of D...
GlobeNewswire
2022-03-15
Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystroph...
GlobeNewswire
2022-03-15
Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
GlobeNewswire
2022-03-11
Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create T...
GlobeNewswire
2022-01-04
Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in ...
GlobeNewswire
2021-12-15
Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
